Opportunistic Infections and Other Risks with Newer Multiple Sclerosis Therapies
Ann Neurol 65:367-377, Berger,J.R. &Houff,S., 2009
Adverse Events Associated with Disease-Modifying Drugs for Multiple Sclerosis
Neurol 102:e208006, Ng, HS.,et al, 2024
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Progressive multifocal leukoencephalpathy after fingolimod treatment
Neurol 90:1815-e1821, Berger, J.R.,et al, 2018
Varicella-Zoster Virus Infections in Patients Treated with Fingolimod
JAMA Neurol 72:31-39,10, Arvin, A.M.,et al, 2015
Cardiovascular Dysfunction in Multiple Sclerosis
Neurologist 20:108-114, Kaplan, T.B.,et al, 2015
Impact of Fingolimod Therapy on Magnetic Resonance Imaging Outcomes in Patients with Multiple Sclerosis
Arch Neurol 69:1259-1269, Radue, E.W.,et al, 2012
Mechanisms of Fingolimods Efficacy and Adverse Effects in Multiple Sclerosis
Ann Neurol 69:759-777, Cohen, J.A. & Chun, J., 2011
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
NEJM 362:402-415, 456, Cohen,J.A.,et al, 2010
Five Cases of Malignant Melanoma During Fingolimod Treatment in Dutch Patients with MS
Neurol 89:970-972, Killestein, J.,et al, 2017